Biotech CEO Sisterhood: Kate Haviland discusses the success factors that led to the $9B+ acquisition of Blueprint Medicines, and the trend of biotech companies taking commercial assets further

Interviewed by Sisterhood editorial board member Daphne Zohar, Kate Haviland talks about the numerous programs that Blueprint created, the rationale behind key go/no-go and partnering decisions, and how she feels about the biotech sector today.